Survival with first-line bosentan in patients with primary pulmonary hypertension

By V. Mclaughlin, O. Sitbon, D. Badesch, Rj Barst, C. Black, N. Galiè, M. Rainisio, G. Simonneau, Lewis J. Rubin. European Respiratory Journal, 2005

617 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1322ae2cea7283ad5a44d72c5a359338ffab38a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau

Citations in the corpus

• Pulmonary arterial hypertension (2013, positive): “Subsequently published data of treatment with bosentan suggested persistent improvements in pulmonary hemodynamics, exercise capacity and modified NYHA functional class and possibly survival rate of patients [229-231].”
• Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. (2006, background): “%) had IPAH; 45% had PAH associated with a variety of conditions, including scleroderma, other connective tissue diseases, HIV infection, repaired congenital heart disease, and anorexigen use.”